

RESEARCH PAPER

Receptor activity-modifying protein-dependent effects of mutations in the calcitonin receptor-like receptor: implications for adrenomedullin and calcitonin gene-related peptide pharmacology

H A Watkins^{1,2}, C S Walker^{1,2}, K N Ly^{1,2}, R J Bailey^{1,2}, J Barwell³,
D R Poyner³ and D L Hay^{1,2}

¹School of Biological Sciences, University of Auckland, Auckland, New Zealand, ²Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland, New Zealand, and ³School of Life Sciences, Aston University, Birmingham, UK

Correspondence

Debbie L Hay, School of Biological Sciences, University of Auckland, Thomas Building, 3A Symonds Street, Private Bag 92019, Auckland 1142, New Zealand. E-mail: dl.hay@auckland.ac.nz

Keywords

adrenomedullin; CGRP; GPCR; receptor activity-modifying protein; RAMP

Received

20 June 2013

Revised

22 October 2013

Accepted

30 October 2013

BACKGROUND AND PURPOSE

Receptor activity-modifying proteins (RAMPs) define the pharmacology of the calcitonin receptor-like receptor (CLR). The interactions of the different RAMPs with this class B GPCR yield high-affinity calcitonin gene-related peptide (CGRP) or adrenomedullin (AM) receptors. However, the mechanism for this is unclear.

EXPERIMENTAL APPROACH

Guided by receptor models, we mutated residues in the N-terminal helix of CLR, RAMP2 and RAMP3 hypothesized to be involved in peptide interactions. These were assayed for cAMP production with AM, AM2 and CGRP together with their cell surface expression. Binding studies were also conducted for selected mutants.

KEY RESULTS

An important domain for peptide interactions on CLR from I32 to I52 was defined. Although I41 was universally important for binding and receptor function, the role of other residues depended on both ligand and RAMP. Peptide binding to CLR/RAMP3 involved a more restricted range of residues than that to CLR/RAMP1 or CLR/RAMP2. E101 of RAMP2 had a major role in AM interactions, and F111/W84 of RAMP2/3 was important with each peptide.

CONCLUSIONS AND IMPLICATIONS

RAMP-dependent effects of CLR mutations suggest that the different RAMPs control accessibility of peptides to binding residues situated on the CLR N-terminus. RAMP3 appears to alter the role of specific residues at the CLR-RAMP interface compared with RAMP1 and RAMP2.

Abbreviations

AM, adrenomedullin; CGRP, calcitonin gene-related peptide; CLR, calcitonin receptor-like receptor; ECD, extracellular N-terminal domain; RAMP, receptor activity-modifying protein

Introduction

Adrenomedullin (AM) and AM₂ (intermedin) are 52 and 47 amino acid peptides that are members of the calcitonin peptide family (Poyner *et al.*, 2002; Hong *et al.*, 2012). This family also includes calcitonin gene-related peptide (CGRP) and amylin. AM is involved in the development of the lymphatic and blood vasculature (Hinson *et al.*, 2000; Fritz-Six *et al.*, 2008; Ichikawa-Shindo *et al.*, 2008). AM₂ is a more recently discovered member of the AM family (Roh *et al.*, 2004; Takei *et al.*, 2004a,b) and, along with AM, has extensive effects on the CVS including vasodilatation, cardioprotection, modulation of vascular tone and stimulation of angiogenesis (Hinson *et al.*, 2000; Fujisawa *et al.*, 2004; Takei *et al.*, 2004a,b).

The AM₁ and AM₂ receptors are class B (secretin family) GPCR (Poyner *et al.*, 2002). However, they differ from many of the other members of this class, as they are formed from the obligate co-expression of the calcitonin receptor-like receptor (CLR) and receptor activity-modifying proteins (RAMP) 2 or 3 respectively. The CGRP receptor is formed of a complex between CLR and RAMP1 (McLatchie *et al.*, 1998). AM and AM₂ both activate AM₁ and AM₂ receptors, although AM₂ has a 10-fold lower potency than AM at the AM₁ receptor (Hong *et al.*, 2012). CGRP also activates AM₁ and AM₂ receptors although with reduced potency compared to AM (McLatchie *et al.*, 1998).

Class B GPCRs consist of a seven transmembrane helical region connected by extra- and intracellular loops; they are characterized by a large extracellular N-terminal domain (ECD). Although to date no full length, peptide-bound class B GPCR structures have been solved, the recent structures of the transmembrane domains of the glucagon- and corticotropin-releasing hormone receptor have given us great insight into the configuration of the transmembrane domain (Hollenstein *et al.*, 2013; Siu *et al.*, 2013). However, neither of these structures captures the native orientation of the ECD with respect to the transmembrane bundle and extracellular loops, although the modelling of the position of the ECD using the glucagon receptor structure may give some indication of its relative orientation (Siu *et al.*, 2013). Crystal structures of isolated ECDs including the glucagon-like peptide-1 receptor (Runge *et al.*, 2008; Underwood *et al.*, 2010), parathyroid hormone (PTH) receptor (Pioszak and Xu, 2008), glucose-dependent insulinotropic polypeptide receptor (Parthier *et al.*, 2007) and the corticotropin-releasing hormone receptors (Pioszak *et al.*, 2008) are available. These structures support the two-domain model of peptide ligand binding (Hoare, 2005; Parthier *et al.*, 2009). This model proposes that the C-terminal of the peptide is captured by the receptor ECD, which induces the formation of an α -helix in the peptide, stabilized by hydrophobic interactions with the receptor ECD. These receptor ECDs share the common 'secretin family recognition fold' consisting of two antiparallel β -sheets and an N-terminal α -helix stabilized by three disulphide bonds. The C-termini of the peptides bind in a common binding groove in the ECD composed of the N-terminal helix, ECD loops 2, 4 and the C-terminal region.

It has long been a challenge to understand how RAMPs allow different peptide preferences. It has been suggested

that RAMPs do this by directly interacting with peptides, by altering the conformation of CLR or a combination of both. However, in attempts to identify the RAMP residues involved very few candidates have been identified (Qi and Hay, 2010). Thus far, in RAMP1 only W84 has a substantial effect on CGRP interactions (Moore *et al.*, 2010). Its equivalent in RAMP2 (F111) has been implicated in AM binding, as has E101 (Kusano *et al.*, 2012). Mutagenesis studies of RAMP1 and RAMP3 indicate that W74 and E74 (the analogous residue in each protein to E101 of RAMP2) are involved in AM selectivity (Hay *et al.*, 2006a; Qi *et al.*, 2008).

The recently determined crystal structures of the CGRP and AM₁ receptor ECDs show that RAMPs interact with CLR by making extensive contacts with its N-terminal α -helix. Although no peptide is bound in any of these structures (ter Haar *et al.*, 2010; Kusano *et al.*, 2012), it has been proposed that due to the high structural similarity of the CLR ECD to the ECD of the parathyroid hormone (PTH)₁ receptor, the peptide-binding groove may be in a similar position in CGRP and AM₁ receptors (Archbold *et al.*, 2011). This is broadly supported by alanine substitution experiments in the CGRP receptor, indicating that CLR residues I32, G35, T37 and I41 in the N-terminal α -helix form a cluster involved in the modification of CGRP interactions (Barwell *et al.*, 2010). Furthermore, in the AM₁ receptor, W72, F92 and W121 of CLR are thought to be involved in AM binding by virtue of the structural similarity of the CLR ECD to other class B ECD structures, which contain bound peptide (Kusano *et al.*, 2012). If this is the case, then most RAMP residues would not be in a position to make major contacts with AM and CGRP, consistent with the lack of residues identified by RAMP mutagenesis. Interestingly, the structures reveal that RAMP2 is slightly rotated with respect to CLR, compared with RAMP1 (Kusano *et al.*, 2012). This RAMP–CLR interaction could affect the exact position of the peptide-binding groove of CLR. An AM₂ (CLR/RAMP3) receptor ECD structure is not available for comparison.

Therefore, there is much evidence pointing towards the notion that RAMP influences the orientation of key residues along the N-terminal α -helix of CLR, although the current ECD structures do not have sufficient resolution to provide details of this. In turn, this could affect the affinity of different peptide ligands for the CGRP, AM₁ and AM₂ receptors. In addition, the conserved aromatic residue at position 84/111 of the three RAMPs may also play a major role in influencing the peptide-binding groove, given its position in the crystal structures of the CGRP and AM₁ receptor ECD.

In order to clarify the role of the RAMPs in ligand binding we compared the effect of mutating residues along the N-terminal α -helix of CLR on different peptides in the presence of different RAMPs. We also mutated the RAMP2 and RAMP3 residues implicated in influencing peptide interactions. We observed striking RAMP-dependent effects on the function of CLR mutants and confirm that the conserved aromatic residue at position 84/111 of RAMP is also a key determinant of peptide interactions. However, we conclude that the RAMPs are particularly important in the control of accessibility to a peptide-binding groove located at the interface between CLR and the RAMP.

Methods

Materials

Human AM (AM 1–52), rat AM (rAM) and human α CGRP were from American Peptide (Sunnyvale, CA, USA). Human AM2 (AM2-47) was from Bachem, Bubendorf, Switzerland. Forskolin was from Tocris Bioscience (Wiltshire, UK). AlphaScreen cAMP assay kits and all reagents and plates were from PerkinElmer (Boston, MA, USA).

Expression constructs and mutagenesis

Human CLR with an N-terminal haemagglutinin (HA) epitope tag, human RAMP2 with an N-terminal FLAG epitope tag (Qi *et al.*, 2013) and untagged human RAMP3 were mutated using a method based on the Quik Change II site-directed mutagenesis kit (Stratagene, Cambridge, UK) as described previously (Conner *et al.*, 2005; Bailey and Hay, 2007). The HA-CLR mutants have previously been described (Barwell *et al.*, 2010).

Cell culture and transfection

Culture of Cos7 cells was performed as previously described (Bailey and Hay, 2006). Cells were cultured in DMEM supplemented with 8% heat-inactivated FBS and 5% (v/v) penicillin/streptomycin and kept in a 37°C humidified 95% air, 5% CO₂ incubator. For cAMP assays, cells were seeded into 96-well plates at a density of 15 000 cells per well (determined using a Countess Counter™, Invitrogen, Carlsbad, CA, USA) 1 day before transfection. Cells were transiently transfected using polyethylenimine (PEI) as described previously (Bailey and Hay, 2006) using a 1:1 ratio of CLR to RAMP. For radioligand binding assays, cells were seeded into 24-well poly-D-lysine-coated plates (BD Biosciences, San Jose, CA, USA) at a density of 75 000 cells per well 1 day before transfection and transfected using PEI; total amount used, 1 µg of DNA per well.

cAMP assay

cAMP assays were performed as previously described (Gingell *et al.*, 2010). Briefly, on the day of the assay, cells were serum-deprived in DMEM containing 1 mM IBMX and 0.1% BSA for 30 min. Peptides, reconstituted to 1 mM in ultra-pure water, were diluted in the same medium to give a final concentration range of 1 pM to 1 µM. Peptides were added to cells and incubated at 37°C for 15 min. The contents of the wells were then aspirated, and 50 µL of ice-cold absolute ethanol was added and allowed to evaporate. cAMP was extracted by adding 40 µL of lysis buffer, and the plates were gently shaken at room temperature for 15 min. Ten microlitres of each cell lysate was transferred to a 384 well plate, followed by 5 µL of acceptor beads, and the plate was sealed and incubated in the dark for 30 min at room temperature. Five microlitres of the donor bead mix was added to all wells; the plate was resealed and incubated in the dark for 16 h. The plates were read using an Envision plate reader (PerkinElmer). The quantity of cAMP produced was determined from the raw data using the cAMP standard curve.

Radioiodination and radioligand binding

rAM was iodinated using iodobeads (Pierce, Rockford, IL, USA). One iodobead was incubated with 100 µg (20 nmol)

rAM and 1 mCi Na¹²⁵I (PerkinElmer) for 5 min at room temperature. Iodinated rAM was purified by reverse phase HPLC. [¹²⁵I]-rAM eluted as a single peak at 26% acetonitrile. Homologous competition radioligand binding assays were conducted on Cos7 cells in 24-well plates. Cells were washed once with warm-binding buffer (DMEM, 0.5% BSA). Wash media were replaced with ice-cold binding buffer followed by binding buffer containing [¹²⁵I]-rAM (approximately 3 pmol, 30 000 cpm per well) and depending on experimental design increasing concentrations of unlabelled peptide. These ranged from 3 µM (non-specific binding) to 10 pM for human AM (hAM) and 10 µM to 10 nM for hAM2 and h α CGRP; each concentration was in duplicate or triplicate. Total binding was assessed in the absence of unlabelled peptide. Cells were then incubated at 4°C for 1 h followed by one wash with ice-cold PBS, pH 7.4 and solubilized in 0.2 M NaOH. Radioactivity was determined using a Wizard2 gamma counter (PerkinElmer).

Analysis of cell surface expression of mutants by ELISA

Cell surface expression of all RAMP/HA-CLR receptor complexes was assessed by measuring HA-CLR expression in an ELISA as previously described (Bailey and Hay, 2007). For selected mutants, FLAG-RAMP2 expression was also measured. Values were normalized to wild-type (WT) RAMP/CLR as 100% and empty vector transfected cells as 0%. In most assays, HA-CLR expression was used for normalization purposes, except in assays specifically measuring FLAG-RAMP2. Statistical significance between WT and mutants was determined by the Kruskal–Wallis test followed by a *post hoc* Dunn's test.

Generation of an AM₂ receptor ECD model

Previously reviewed RAMP1 and RAMP3 full-length sequences were downloaded from the UniProt server, and a multiple sequence alignment was generated using the T-Coffee server (Poirot *et al.*, 2003). Modeller9v8 (Sali and Blundell, 1993; Fiser and Sali, 2003) was used to generate 500 models of CLR/RAMP3 ECD using chains A and D from the protein database (PDB) accession 3N7S as templates. RAMP3 had a standard N-terminus cap whereas CLR contained an acetylated N-terminus. Both RAMP3 and CLR contained N-methylamide C-termini. This modification prevents unnecessary large electrostatic attractive forces between the ends of the protein fragment during energy minimization. The models were ranked by the Modeller9v8 energy objective function. The top 10 structures were retained, and the stereochemical quality was assessed by PROCHECK v3.5.4 (Laskowski *et al.*, 1993; Laskowski, 2001). Based on overall and residue-by-residue geometry a structure was selected. The ProPka programme (Li *et al.*, 2005) via the PDBQPR server (see Dolinsky *et al.*, 2007) was used to assign the protonation states of the titratable groups in CLR ECD, using the Chemistry at HARvard Molecular Mechanics (CHARMM) parameters set at pH 7.0. The CHARMM (c35b3) module Screened Coulomb Potentials Implicit Solvent Model was used to minimize the model. One hundred steps of steepest descent were conducted followed by adopted basis Newton–Raphson minimization until convergence was met.

Data analysis

Data analysis was performed in GraphPad Prism 6 (GraphPad Software Inc., San Diego, CA, USA). Data were fitted to obtain concentration–response curves using a four parameter logistic equation, and an *F*-test was conducted to compare whether the Hill slope of the curves was significantly different from 1. In most analyses, the Hill slope was not different from 1 and was therefore constrained to 1. From these curves, pEC_{50} values were obtained. Data were normalized in each experiment to the fitted minimum and maximum of the WT curve on each assay plate. E_{max} values from these curves are reported. The means of replicates from these individual experiments were combined to generate the curves that are shown. pEC_{50} and E_{max} values are presented as the mean $\pm$ SEM of values from individual data sets and were tested for statistical significance versus WT using a paired *t*-test. For radioligand binding assays specific binding was calculated by subtraction of non-specific binding (the highest unlabelled hAM concentration). Binding curves were analysed as for cAMP assays and normalized to their fitted minimum and maximum. pIC_{50} values from these curves are reported and tested for statistical significance using an unpaired *t*-test. Curves are presented as the combined means of data from each unlabelled hAM concentration for each individual experimental repeat. For the determination of relative binding for each of the mutant receptors compared with WT, specific binding data were normalized to the mean of specific binding for the WT receptor and an overall mean value calculated and analysed for statistical significance using the Kruskal–Wallis test followed by a *post hoc* Dunn's test. For all assays, significance was accepted at $P < 0.05$.

Results

Selection of residues in CLR, RAMP2 and RAMP3

We used the CGRP and AM₁ receptor structures along with the residues involved in CGRP binding at the CGRP receptor to guide this study of residues potentially involved in peptide–receptor interactions (Barwell *et al.*, 2010; ter Haar *et al.*, 2010; Kusano *et al.*, 2012). Residues along the exposed face of the CLR ECD helix ranging from V36 to I41 were selected for alanine substitution. We also focused on a region of importance in the CGRP receptor N-terminal to this helix and beyond the extent of the crystal structures between residues I32 and G35. Proceeding further along the same face of the ECD helix as I41, we did not test C48 as this forms a disulphide bond with C74, which is integral to the structural integrity of the ECD. Y49 is predicted to form part of the RAMP2/CLR interface (ter Haar *et al.*, 2010; Kusano *et al.*, 2012). We therefore tested this for cell surface expression. To further refine the limits of the binding pocket, the next residue whose effect we tested along the ECD helix was I52. We also tested two RAMP2 residues that are in the vicinity of I41 (E101, F111) and the corresponding RAMP3 residue (W84). Mutant receptors were assayed for cAMP production at the AM₁, AM₂ and CGRP receptors when stimulated with hAM or hAM2. The AM₂ receptor was also stimulated with hαCGRP. hαCGRP was not used to stimulate the AM₁ receptor

due to its very low binding affinity and potency at this receptor (McLatchie *et al.*, 1998; Aiyar *et al.*, 2001; Poyner *et al.*, 2002).

Residues in the CLR ECD in the AM₁ receptor – stimulation of cAMP production

At the AM₁ receptor the point mutants I32A, Q33A, G35A and V36A had no effect on AM potency (Table 1). L34A, T37A, I41A, M42A, Q45A and I52A all showed a decrease in AM potency, although the effect of T37A was not statistically significant (Table 1; Figure 1). I41A had the largest effect. AM₂ potency at the AM₁ receptor was affected in a similar manner to AM; however, in this case very large reductions in potency were seen for T37A, I41A and Q45A. No change was seen in AM₂ potency for I52A, and a small reduction in potency was observed for G35A. E_{max} was substantially decreased for I41A and Q45A when the AM₁ receptor was stimulated with AM and AM₂. The E_{max} for Q33A with both ligands was substantially increased. E_{max} data are also presented in Supporting Information Figure S1 for easy comparison between receptors and peptides.

Residues in the CLR ECD in the AM₂ receptor – stimulation of cAMP production

At the AM₂ receptor I32A, Q33A, V36A, M42A, Q45A and I52A had no effect on the potency of AM, AM₂ or hαCGRP (Table 2). L34A and G35A decreased AM potency. T37A and I41A had a substantial effect on AM and AM₂ potency. Only T37A and I41A had major effects on hαCGRP, with large reductions in E_{max} (Table 2, Figure 2). No significant effects on E_{max} were observed with any ligand for Q33A and Q45A.

Residues in the CLR ECD in the CGRP receptor – stimulation of cAMP production

A similar study has been carried out to assess the effects of these mutations on CGRP potency at the CGRP receptor (Barwell *et al.*, 2010). To provide an accurate comparison with all three RAMPs, we additionally studied the effects of selected mutations on AM and AM₂ in the CGRP receptor. For AM, only I41A affected potency and only Q45A affected E_{max} (Table 3; Figure 3). More effects were seen with AM₂; G35A, T37A, I41A and Q45A all showed a decrease in potency. E_{max} values were also decreased for I41A and Q45A. The E_{max} was increased for AM₂ at the I32A CGRP receptor.

Residues in the RAMP2 ECD in the AM₁ receptor – stimulation of cAMP production

E101A and F111A mutations in RAMP2 both substantially affected receptor function (Table 4; Figure 4). For E101A this was evident as a 20-fold reduction in AM potency. With F111A, potency was apparently preserved but there was a large reduction in E_{max} . Due to the low E_{max} , the potency estimate should be treated with caution. Both residues also affected AM₂-mediated receptor activation in a similar fashion.

Residues in the RAMP3 ECD in the AM₂ receptor – stimulation of cAMP production

We have previously extensively characterized mutations at E74 of RAMP3, the equivalent to E101 in RAMP2 (Hay *et al.*,

Table 1Summary of pEC₅₀ and E_{max} values for mutants of CLR in the AM₁ receptor when stimulated with hAM or hAM2

	hAM				hAM2			
	WT	Mutant	E _{max} %WT	n	WT	Mutant	E _{max} %WT	n
CLR I32A	9.07 ± 0.21	9.21 ± 0.27	133.9 ± 19.4	3	8.23 ± 0.03	8.24 ± 0.09	110.7 ± 15.5	3
CLR Q33A	9.06 ± 0.06	9.15 ± 0.05	269.4 ± 44.2*	4	8.12 ± 0.09	7.89 ± 0.12	281.0 ± 92.5	4
CLR L34A	8.89 ± 0.03	8.50 ± 0.09*	104.7 ± 42.9	3	8.25 ± 0.16	7.64 ± 0.20**	117.9 ± 17.9	4
CLR G35A	9.07 ± 0.22	8.91 ± 0.23	139.9 ± 26.8	3	8.22 ± 0.02	7.92 ± 0.03*	92.9 ± 3.07	3
CLR V36A	9.07 ± 0.22	8.92 ± 0.25	138.2 ± 19.8	3	8.22 ± 0.02	7.89 ± 0.18	153.9 ± 50.8	3
CLR T37A	8.94 ± 0.13	8.25 ± 0.19	89.0 ± 9.96	3	8.12 ± 0.26	6.99 ± 0.21	70.6 ± 12.1	2 ^a
CLR I41A	9.14 ± 0.18	7.91 ± 0.34*	33.7 ± 2.37***	4	8.21 ± 0.34	No curve		3
CLR M42A	9.11 ± 0.05	8.48 ± 0.08*	139.6 ± 36.9	3	8.21 ± 0.10	7.86 ± 0.13	89.9 ± 26.6	4
CLR Q45A	9.03 ± 0.19	8.45 ± 0.22***	26.1 ± 8.61**	5	8.48 ± 0.24	No curve		3
CLR I52A	9.05 ± 0.16	8.66 ± 0.20*	136.1 ± 33.6	6	8.03 ± 0.17	8.11 ± 0.24	94.6 ± 9.00	3

Data are the mean ± SEM of *n* individual data sets.**P* < 0.05; ***P* < 0.01; ****P* < 0.001 versus WT receptor by paired *t*-test.^aIn two other experiments, the mutant did not produce any measurable response. 'No curve' indicates that the mutation abolished measurable receptor function.

2006b; Qi *et al.*, 2008). The RAMP3 equivalent to F111 is W84. W84A resulted in a large decrease in AM potency and E_{max}, a smaller decrease in AM2 potency but a large decrease in E_{max} and complete abolition of hαCGRP responses (Table 4; Figure 5). The conservative mutation of W84F partially restored receptor function, with less perturbation of potency and E_{max}. AM potency was reduced only threefold with this mutation, and AM2 potency was not significantly reduced. hαCGRP responses were measurable with this mutation. A summary of all cAMP data is presented in Figure 6.

Residues in the CLR ECD in the AM₁ and AM₂ receptors – ligand binding

We used a whole-cell ¹²⁵IrAM binding assay to determine the relative affinities of AM, AM2 and hαCGRP at the AM₁ receptor. hAM had a mean pIC₅₀ of 8.29 ± 0.25 (*n* = 4) and hαCGRP showed very weak binding (Figure 7), consistent with literature reports (Aiyar *et al.*, 2001). hAM2 showed a 10-fold lower pIC₅₀ than hAM (7.25 ± 0.05, *n* = 4, *P* < 0.01 by unpaired *t*-test), consistent with their rank order of potency (Hong *et al.*, 2012).

Our cAMP assays indicated some differences in the role of CLR ECD residues between the AM₁ and AM₂ receptors. To further investigate this, we performed radioligand binding assays on selected mutants. Specific binding was abolished at both receptors for T37A and I41A (Figure 7). Binding was also abolished at the AM₁ receptor with M42A and Q45A. Interestingly, specific binding was retained for both of these mutants at the AM₂ receptor, in line with the cAMP data. Given that Q45A also showed a large differential effect in cAMP assays, we determined the pIC₅₀ for AM at the AM₂ receptor. This was 7.51 ± 0.21 (*n* = 3). The WT pIC₅₀ was 7.69 ± 0.11 (*n* = 3); there was no significant difference between

these values. Only I52A retained binding at the AM₁ receptor and full-curve analysis showed no difference in pIC₅₀ for AM compared with WT [8.02 ± 0.03 (*n* = 3) for I52A vs. 8.29 ± 0.25 (*n* = 4) for WT].

Cell surface expression

The CLR and RAMP2 or RAMP3 components are individually expressed inefficiently at the cell surface (McLatchie *et al.*, 1998); however, when either RAMP2 or RAMP3 is expressed together with CLR, they are translocated to the cell surface to form functional AM₁ or AM₂ receptors respectively. The presence of HA-CLR at the cell surface can therefore be used as an estimate of AM receptor complex expression. To determine whether a change in binding or peptide responsiveness with the mutations was due to perturbed cell surface expression, we performed whole-cell ELISAs. For almost all mutants, the mean expression was within 50% of WT and any reduction was not statistically significant (Table 5). Previously, we have shown that reductions of less than 50% in cell surface expression in our Cos7 cells do not substantially perturb cAMP responsiveness (Bailey and Hay, 2007). Only Y49A at the AM₁ receptor and W84A RAMP3 in the AM₂ receptor (Table 5) caused a significant reduction in HA-CLR expression. As Q45A and Y49A are found at the interface between CLR and RAMP2, we additionally tested FLAG-RAMP2 expression for these two mutants to determine whether any reduction in CLR expression was likely to be caused by a disruption in CLR/RAMP2 complex formation. The results were consistent with the HA-CLR measurements with FLAG-RAMP2 expression only significantly reduced with the Y49A mutation (13.1 ± 12.5%, *n* = 4, *P* < 0.01 by Kruskal–Wallis test followed by Dunn's test) and reduced to a lesser degree with the Q45A mutation (73.5 ± 10.7%, *n* = 3).




Figure 1

hAM and hAM2 stimulated cAMP responses of CLR mutant AM₁ receptors. Normalized data were combined and data points shown are mean $\pm$ SEM of at least three individual data sets. Normalization is relative to the paired fitted maximal and basal cAMP production of the WT receptor.

Table 2

Summary of pEC₅₀ and E_{max} values for mutants of CLR in the AM₂ receptor when stimulated with hAM₁, hAM₂ or hαCGRP

	hAM			hAM ₂			hαCGRP		
	WT	Mutant	E _{max} %WT	n	WT	Mutant	E _{max} %WT	n	E _{max} %WT
CLR I32A	9.54 ± 0.11	9.36 ± 0.13	135.2 ± 13.8	4	9.83 ± 0.13	9.47 ± 0.22	129.3 ± 30.7	3	72.7 ± 20.3
CLR Q33A	9.46 ± 0.11	9.61 ± 0.09	127.2 ± 19.2	3	8.59 ± 0.22	8.56 ± 0.14	155.2 ± 23.2	3	196.6 ± 40.7
CLR L34A	9.59 ± 0.06	8.88 ± 0.15**	139.5 ± 19.3	4	9.42 ± 0.11	9.13 ± 0.16	104.5 ± 22.0	3	99.8 ± 7.96
CLR G35A	9.29 ± 0.24	8.77 ± 0.18*	71.0 ± 11.8	3	9.09 ± 0.22	8.78 ± 0.12	97.9 ± 21.0	3	53.3 ± 16.3
CLR V36A	9.29 ± 0.24	9.06 ± 0.25	89.9 ± 5.71	3	9.09 ± 0.22	8.62 ± 0.19	121.0 ± 17.1	3	70.5 ± 9.21
CLR T37A	9.61 ± 0.20	8.63 ± 0.03*	90.1 ± 17.1	3	9.13 ± 0.25	7.70 ± 0.14**	68.5 ± 10.6	3	59.1 ± 10.2*
CLR I41A	9.80 ± 0.13	8.51 ± 0.15**	77.6 ± 9.69	4	9.32 ± 0.28	8.47 ± 0.34**	87.4 ± 11.8	3	No curve
CLR M42A	9.66 ± 0.30	9.52 ± 0.17	150.1 ± 32.0	4	8.82 ± 0.17	8.61 ± 0.11	262.8 ± 95.2	3	67.4 ± 19.0
CLR Q45A	9.61 ± 0.23	9.40 ± 0.16	138.3 ± 30.0	3	8.95 ± 0.10	8.94 ± 0.09	104.6 ± 16.9	4	112.2 ± 35.4
CLR I52A	9.55 ± 0.17	9.36 ± 0.22	97.5 ± 5.32	4	9.29 ± 0.14	9.12 ± 0.16	71.8 ± 22.4	3	108.8 ± 36.2

Data are the mean ± SEM of *n* individual data sets.**P* < 0.05; ***P* < 0.01; ****P* < 0.001 versus WT receptor by paired *t*-test. 'No curve' indicates that the mutation abolished measurable receptor function.

Discussion

The recently solved crystal structures of the AM₁ and CGRP receptor ECDs have greatly expanded our understanding of these receptors and the interaction of their common CLR subunit with these two different RAMPs. Of these, the CGRP receptor ECD is the most complete, especially at the N-terminus of CLR. However, the lack of bound peptides in these structures gives us limited insight into the manner of peptide binding to these receptors. Mutagenesis studies pinpointed the extreme N-terminus of CLR as a key determinant of CGRP binding to the CGRP receptor ECD. We have now defined an essential region for peptide binding in the three CLR-based receptors (Figure 6; Supporting Information Figure S1). This centres around I41 with contributions from T37 and Q45, and lesser contributions from I32, Q33, L34, G35, M42 and I52, depending on the RAMP co-expressed. These residues mainly contribute to agonist binding and thus potency, although, especially for I32 and Q33, there are effects on E_{max}. We observed potentially important differences in the function of CLR residues in the presence of RAMP3, compared with RAMP1 and RAMP2.

The N-terminus of CLR is predominantly helical, although the region N-terminal to T37 in the CGRP receptor structure is somewhat disordered. In one of the three structures (3N7P) of the CGRP receptor ECD (3N7P, 3N7R and 3N7S), it is not helical and in all structures the atoms have high b-factors, indicating significant mobility (ter Haar *et al.*, 2010; Barwell *et al.*, 2012). These extreme N-terminal residues lie beyond the extent of the AM₁ receptor structure. Interestingly, this region has very low-sequence identity across species compared with the rest of the N-terminal region (Supporting Information Figure S2), and the periodicity of these residues implies that this region may not be helical. The ability of I32 and Q33 to increase E_{max} may mean that these residues are able to influence ligand binding to the transmembrane core or the conformation of CLR to promote coupling to Gs, possibly via an interaction with one of the extracellular loops of the receptor. However, without a full-length (ligand-bound) receptor structure their steric relationship to the transmembrane bundle and extracellular loops is speculative.

T37, I41 and Q45 are highly conserved across species (Supporting Information Figure S2), and each has interesting effects upon mutation in the three CLR-based receptors. These residues all lie on the same face of the N-terminal CLR helix, and in the CGRP and AM₁ receptor ECD crystal structures have their side chains projecting upwards into a groove between CLR and the RAMP, in a good position to interact with a ligand that might bind in this area.

I41 is universally important for cAMP accumulation and binding; it has also been shown to be important for the binding of CGRP to the CGRP receptor (Barwell *et al.*, 2010). The equivalent residue is important for glucagon binding to the glucagon receptor (Siu *et al.*, 2013). The hydrophobic side chain of I41 is in an exposed position, at the entrance to the interface between CLR and all three RAMPs (Figure 8). We suggest that it acts as a pivot point for peptide binding and is probably a direct contact for all three agonists.

Beyond I41, the accessibility of the residues on the CLR helix sharply decreases (Figure 8), although the details of this




Figure 2

hAM, hAM₂ and hαCGRP stimulated cAMP responses of CLR mutant AM₂ receptors. Normalized data were combined and data points shown are mean ± SEM of at least three individual data sets. Normalization is relative to the paired fitted maximal and basal cAMP production of the WT receptor.

Table 3Summary of pEC₅₀ and E_{max} values for mutants of CLR in the CGRP receptor when stimulated with hAM or hAM2

	hAM				hAM2			
	WT	Mutant	E _{max} %WT	n	WT	Mutant	E _{max} %WT	n
CLR I32A	8.35 ± 0.14	8.33 ± 0.14	82.8 ± 16.5	4	8.42 ± 0.22	8.52 ± 0.33	141.9 ± 6.01*	3
CLR L34A	8.49 ± 0.25	8.64 ± 0.09	87.8 ± 6.35	3	8.51 ± 0.20	8.44 ± 0.10	358.9 ± 118.4	3
CLR G35A	8.41 ± 0.17	8.21 ± 0.14	112.1 ± 11.1	3	8.40 ± 0.20	8.04 ± 0.20*	149.8 ± 41.1	4
CLR V36A	8.22 ± 0.06	8.25 ± 0.08	124.3 ± 26.3	3	8.42 ± 0.22	8.21 ± 0.25	127.3 ± 19.8	3
CLR T37A	8.36 ± 0.27	8.09 ± 0.21	125.4 ± 20.6	3	8.31 ± 0.19	7.47 ± 0.26*	83.0 ± 15.2	3
CLR I41A	8.54 ± 0.16	7.47 ± 0.13*	68.4 ± 11.4	4	8.31 ± 0.19	7.23 ± 0.34*	57.4 ± 8.66*	3
CLR M42A	8.36 ± 0.27	8.25 ± 0.21	106.9 ± 26.8	3	8.33 ± 0.20	8.27 ± 0.20	92.5 ± 9.76	3
CLR Q45A	8.23 ± 0.25	7.87 ± 0.13	49.9 ± 4.27**	3	8.65 ± 0.07	7.97 ± 0.08*	34.7 ± 9.56*	3

Data are the mean ± SEM of *n* individual data sets.**P* < 0.05; ***P* < 0.01 versus WT receptor by paired *t*-test. To confirm cross-compatibility of assays, an experiment with CGRP under the same assay conditions as for AM and AM2 gave values of 10.1 for the WT receptor and 9.09 for the I41A CGRP receptor, consistent with the findings of Barwell *et al.* (2010).

are RAMP-dependent (ter Haar *et al.*, 2010; Kusano *et al.*, 2012). The side chain of M42 is perpendicular to those of T37, I41 and Q45 and points towards the RAMP. Although it is sufficiently accessible to be important for the binding of non-peptide antagonists to the CGRP receptor (ter Haar *et al.*, 2010; Miller *et al.*, 2010), this change of angle is likely to make it particularly inaccessible to any peptide orientated parallel to the main axis of the CLR N-terminal helix. Its effect on hAM binding and small effect on hAM potency in the AM₁ receptor may not therefore be due to a direct interaction with the peptide but to a localized disruption of the structure of the AM-binding pocket.

The side chains of Q45 and Y49, although favourably orientated for peptide binding, are also deep enough within the CLR/RAMP interface to interact with conserved tyrosine residues in RAMP1 and RAMP2. The effects of Y49 are particularly notable; mutation of this residue abolishes binding and substantially reduces expression in the CGRP receptor (Barwell *et al.*, 2010). Similar effects on cell surface expression are seen in the AM₁ receptor. These data suggest that the main effect of Y49 is to stabilize the CLR/RAMP interface in the CGRP and AM₁ receptors, rather than having a direct effect on ligand binding. In contrast, the major effect of Q45A on the AM₁ receptor is most likely to be due to an effect on the peptide-binding pocket, perhaps as a contact for AM. Like Y49A, this residue shows intriguing differential behaviour in the presence of RAMP3. This will be explored further below.

I52 is situated on the opposite face of the ECD to the proposed peptide-binding cleft and is not readily accessible to ligand, consistent with its very minor role in binding and peptide responsiveness at each of the three receptors (Barwell *et al.*, 2010). The crystal structures of ligand-free or antagonist-bound receptors in the absence of the transmembrane domains of either CLR or RAMP may of course not be an accurate reflection of the agonist-bound state of the intact receptors; in particular, there may be rearrangements to increase accessibility of the binding groove in the CLR-RAMP

interface. Nonetheless, it is reasonable to assume that the residues C-terminal to I41A will remain partly buried.

The proposed essential binding residues of the three receptors are presented in Figure 8. The RAMP residue W84/F111 is similarly involved in all of the binding pockets and is conserved within each RAMP across a wide range of species (Hay *et al.*, 2006a). Interestingly, the W74/E101/E74 position is only hydrophobic in RAMP1 where its mutation causes an increase in AM and AM2 binding but has no effect on CGRP binding (Figure 8) (Qi *et al.*, 2008; Moore *et al.*, 2010). The conserved polar residue E101 (W74 in RAMP1) is not particularly prominent, being situated further back in the AM₁ receptor binding pocket. However, it may still form the top of our putative peptide-binding pocket as it does have a substantial role to play in AM potency at the AM₁ and AM₂ receptors. These effects correspond with the decrease in binding affinity of AM to these mutants at the AM₁ receptor ECD, as determined using surface plasmon resonance (Kusano *et al.*, 2012). Mutation of this position has fewer effects on AM2 potency at both receptors (Qi *et al.*, 2011). Taken together with the position of all of these residues in the AM₁ receptor ECD crystal structure, the data collectively suggest that the CLR residues from I41 and the RAMP2 residue F111 form a hydrophobic area at the back of the peptide-binding groove. E101 forms a polar sub-region of this area that may contribute to ligand selectivity between the AM₁, AM₂ and CGRP receptors. A similar hydrophobic region is formed by I41 and the corresponding RAMP1 residues W74 and W84 in the CGRP receptor crystal structure (ter Haar *et al.*, 2010). Our data and model of the AM₂ receptor ECD suggest that the top of the pocket may be formed in an analogous manner. There are a number of hydrophobic regions in the C-terminal region of CGRP, AM and AM2 that could dock in such an environment. For example, the C-terminal amide residue of the three peptides is a conserved aromatic residue (Tyr or Phe), which is essential for the binding of AM₂₂₋₅₂ and CGRP derivatives (Watkins *et al.*, 2012; 2013; Moad and Pioszak, 2013). The




Figure 3

hAM and hAM2 stimulated cAMP responses of CLR mutant CGRP receptors. Normalized data were combined and data points shown are mean $\pm$ SEM of at least three individual data sets. Normalization is relative to the paired fitted maximal and basal cAMP production of the WT receptor.

Table 4

Summary of pEC₅₀ and E_{max} values for RAMP2 and RAMP3 mutants in the AM₁ and AM₂ receptors, respectively, when stimulated with hAM, hAM₂ or hαCGRP

	hAM				hAM2				hαCGRP			
	WT	Mutant	$E_{\max}$ %WT	n	WT	Mutant	$E_{\max}$ %WT	n	WT	Mutant	$E_{\max}$ %WT	n
RAMP2 E101A	9.06 ± 0.15	7.75 ± 0.30*	71.1 ± 14.7	4	8.10 ± 0.05	7.39 ± 0.13	74.1 ± 14.8	3	–	–	–	–
RAMP2 F111A	9.06 ± 0.15	8.94 ± 0.29	39.2 ± 10.6*	4	8.10 ± 0.05	No curve	No curve	3	–	–	–	–
RAMP3 W84A	9.64 ± 0.13	8.78 ± 0.23*	59.0 ± 5.99**	4	9.62 ± 0.08	9.02 ± 0.06**	42.3 ± 3.34***	4	6.91 ± 0.15	No curve	No curve	4
RAMP3 W84F	9.58 ± 0.04	9.08 ± 0.07**	72.6 ± 8.90	4	9.63 ± 0.08	9.38 ± 0.07	61.8 ± 7.21*	4	7.06 ± 0.07	6.12 ± 0.09***	54.1 ± 5.34	4

Data are the mean ± SEM of *n* individual data sets.

P* < 0.05; *P* < 0.01; ****P* < 0.001 versus WT receptor by paired *t*-test. 'No curve' indicates that the mutation abolished measurable receptor function. – indicates experiment not performed due to low-ligand potency.

Table 5

Summary of cell surface expression data for HA-CLR in mutant AM₁ and AM₂ receptors

Mutant	AM ₁ receptor	AM ₂ receptor
	HA-CLR %WT	HA-CLR %WT
CLR I32A	83.1 ± 6.71 (3)	113.7 ± 25.8 (3)
CLR Q33A	115.8 ± 33.9 (3)	116.2 ± 14.2 (5)
CLR L34A	95.5 ± 7.54 (4)	107.2 ± 7.15 (3)
CLR G35A	90.8 ± 10.4 (3)	94.7 ± 8.95 (3)
CLR V36A	78.5 ± 8.74 (3)	96.9 ± 2.28 (3)
CLR T37A	80.5 ± 10.3 (3)	126.5 ± 12.5 (5)
CLR I41A	65.7 ± 9.52 (5)	86.4 ± 9.69 (3)
CLR M42A	123.7 ± 20.9 (3)	112.8 ± 19.4 (5)
CLR Q45A	61.5 ± 5.91 (3)	104.9 ± 12.8 (3)
CLR Y49A	25.9 ± 7.91 (4)**	111.6 ± 8.25 (4)
CLR I52A	98.7 ± 7.11 (3)	116.2 ± 19.5 (3)
RAMP2 E101A	98.78 ± 10.4 (4)	–
RAMP2 F111A	95.79 ± 13.1 (4)	–
RAMP3 W84A	–	47.7 ± 4.67 (6)*
RAMP3 W84F	–	63.6 ± 3.79 (4)

Data are the mean ± SEM of *n* individual data sets (in parentheses).

P* < 0.05; *P* < 0.01 versus WT receptor by the Kruskal–Wallis test followed by Dunn's multiple comparison test. –, not applicable.

aromatic side chain of this residue could form hydrophobic interactions or pi–pi stacking in this area (Archbold *et al.*, 2011). Peptide binding to class B GPCRs ECDs involves the formation of hydrophobic interactions that result in the formation of an α-helix in the peptide ligand (Parthier *et al.*, 2009). The mutation of hydrophobic residues along the CLR ECD helix and at the top of our proposed binding pocket could therefore affect ligand structure as well as peptide binding.

It is possible to comment on some general features of RAMP action and their implications for peptide binding. A greater number of residues in CLR investigated in this study are involved in peptide interactions with RAMP1 and RAMP2, compared with RAMP3 (Figure 6). This is particularly striking for M42 and Q45, which do not influence peptide binding to the AM₂ receptor. We propose that RAMP3 either orientates all three peptides at an angle so as to miss the main part of the groove between it and CLR, or it changes the shape of the groove. The latter proposition is supported by the differential effect of Y49A on CLR cell surface expression with RAMP1, RAMP2 and RAMP3. The reduction with RAMP1 and RAMP2 confirm that this is an important interface residue between these RAMPs and CLR. However, the data strongly suggest that Y49 may not assume the same role in CLR/RAMP3 complexes. However, our CLR/RAMP3 ECD model cannot inform us as to any possible differences in the interface between CLR and RAMP3 compared with the other RAMPs, because it is a




Figure 4

hAM and hAM2 stimulated cAMP responses of RAMP2 mutant AM_1 receptors. Normalized data were combined and data points shown are mean $\pm$ SEM of at least three individual data sets. Normalization is relative to the paired fitted maximal and basal cAMP production of the WT receptor.




Figure 5

hAM, hAM2 and h α CGRP stimulated cAMP responses of RAMP3 mutant AM_2 receptors. Normalized data were combined and data points shown are mean $\pm$ SEM of at least three individual data sets. Normalization is relative to the paired fitted maximal and basal cAMP production of the WT receptor.




Figure 6

Effect of mutations in the N-terminal CLR residues on pEC_{50} values. Data are ordered to show the effect induced by RAMP (left) or peptide (right). The $\Delta\log EC_{50}$ values were calculated by subtracting the mean pEC_{50} for a given ligand at a given mutation from the mean of its paired WT control. For comparisons with the CGRP receptor, these values were calculated from the data presented in Barwell *et al.* (2010). Values above the line are an increase in potency and below the line are a decrease. Where the mutation abolished measurable receptor function, an arbitrary value of two has been assigned.




Figure 7

Effect of mutations in N-terminal CLR residues on ligand binding. (A) Competitive binding curves showing the displacement of [¹²⁵I]-rAM by hAM, hAM2 and hαCGRP at the AM₁ receptor. (B) Specific binding of [¹²⁵I]-rAM to selected CLR mutants at the AM₁ receptor expressed as a percentage of WT binding (100%). (C) Specific binding of [¹²⁵I]-rAM to selected CLR mutants at the AM₂ receptor expressed as a percentage of WT binding (100%). (D) Competitive binding curves showing the displacement of [¹²⁵I]-rAM by hAM for I52A in the AM₁ receptor and Q45A in the AM₂ receptor, compared with WT controls. Data were combined and data points shown are mean ± SEM of at least three individual data sets.

homology model based on the CGRP receptor ECD structure. A crystal structure of the CLR/RAMP3 ECD is needed to determine the specific position of residues at the interface between these proteins. Nonetheless, the idea that the interface is different between each CLR/RAMP complex is also supported by mutation of the RAMP residue (W84/F111), which has modest effects on cell surface expression with RAMP1 and RAMP3 but not RAMP2 (Moore *et al.*, 2010). This position may have a dual role in ligand binding and stabilization of the RAMP/CLR interface, depending on the RAMP.

In contrast to RAMP3, RAMP1 and RAMP2 support the involvement of more N-terminal helix residues, suggesting that the peptides lie parallel to these. CGRP and AM2 may sit slightly further forward (to the N-terminus of the CLR helix) than AM, depending on the RAMP. This is unlike the situation found for the majority of other class B GPCR ECDs that do not require a RAMP. In these cases, the bound peptide is at approximately 45° to the ECD helix, with the C-terminal

amide (where present in the structure) binding to a residue in loop 4 of the receptor ECD, although the precise orientation of the individual peptides differs (Pioszak and Xu, 2008; Pioszak *et al.*, 2009; Pal *et al.*, 2010; Archbold *et al.*, 2011). Regardless of the precise peptide orientation in each class B GPCR, binding to the receptor ECD helix occurs at the approximate position of I41 of CLR, as we have proposed for cognate peptide binding to the CGRP, AM₁ and AM₂ receptors.

We suggest that the binding mode of CGRP, AM and AM2 to their receptors is broadly similar to other class B GPCRs, but that the RAMP alters the conformation of the CLR to influence ligand affinity and thus potency. In particular, it controls accessibility of the peptide-binding epitope on the N-terminus of the CLR, particularly where this is itself part of the CLR-RAMP interface. In addition, there are direct interactions from two key residues positioned at 74/101 and 84/111 in the RAMPs (Figure 8). This results in a slightly




Figure 8

Figure depicting the amino acid residues likely to be involved in peptide binding, generated using PyMol. (A) CGRP-binding residues in the CGRP receptor ECD (3N7S; a representative structure for the CGRP receptor), as previously determined by alanine scanning mutagenesis (Barwell *et al.*, 2010). (B) AM-binding residues in the CGRP receptor. (C) AM-binding residues in the AM₁ receptor ECD (3AQF). The AM₁ receptor structure is N-terminally truncated to V36; thus, many residues involved in AM binding could not be depicted. This may indicate increased mobility of this region of the receptor ECD. (D) AM-binding residues in our AM₂ receptor ECD model. RAMP1 is shown in blue, RAMP2 in yellow, RAMP3 in pale blue and CLR in green. Residues where substitution resulted in a decrease in peptide potency are shown in red; those that cause an increase in potency are shown in orange. In each part of the figure, (i) shows secondary structural elements with residues involved represented as sticks and (ii) shows the surface map.

different manner of binding for the AM, AM2 and CGRP peptides across the three receptors. Subtle differences in CLR ECD conformation with each RAMP could affect the function of the receptor as a whole. This could be reflected further downstream in terms of differential receptor signalling. Structure-based drug design at these receptors will need to take these factors into account.

Acknowledgements

We thank the New Zealand Lotteries Commission (Health), Maurice and Phyllis Paykel Trust, National Heart Foundation of New Zealand and Health Research Council of New Zealand for support. D. R. P. and J. B. acknowledge support of the Wellcome Trust (grant 091496).

Conflict of interest

None for any author.

References

- Aiyar N, Disa J, Pullen M, Nambi P (2001). Receptor activity modifying proteins interaction with human and porcine calcitonin receptor-like receptor (CRLR) in HEK-293 cells. *Mol Cell Biochem* 224: 123–133.
- Archbold JK, Flanagan JU, Watkins HA, Gingell JJ, Hay DL (2011). Structural insights into RAMP modification of secretin family G protein-coupled receptors: implications for drug development. *Trends Pharmacol Sci* 32: 591–600.
- Bailey RJ, Hay DL (2006). Pharmacology of the human CGRP1 receptor in Cos 7 cells. *Peptides* 27: 1367–1375.
- Bailey RJ, Hay DL (2007). Agonist-dependent consequences of proline to alanine substitution in the transmembrane helices of the calcitonin receptor. *Br J Pharmacol* 151: 678–687.
- Barwell J, Miller PS, Donnelly D, Poyner DR (2010). Mapping interaction sites within the N-terminus of the calcitonin gene-related peptide receptor; the role of residues 23–60 of the calcitonin receptor-like receptor. *Peptides* 31: 170–176.
- Barwell J, Gingell JJ, Watkins HA, Archbold JK, Poyner DR, Hay DL (2012). Calcitonin and calcitonin receptor-like receptors: common themes with family B GPCRs? *Br J Pharmacol* 166: 51–65.
- Conner AC, Hay DL, Simms J, Howitt SG, Schindler M, Smith DM *et al.* (2005). A key role for transmembrane prolines in calcitonin receptor-like receptor agonist binding and signalling: implications for family B G-protein-coupled receptors. *Mol Pharmacol* 67: 20–31.
- Dolinsky TJ, Czodrowski P, Li H, Nielsen JE, Jensen JH, Klebe G *et al.* (2007). PDB2PQR: expanding and upgrading automated preparation of biomolecular structures for molecular simulations. *Nucleic Acids Res* 35: W522–W525.
- Fiser A, Sali A (2003). Modeller: generation and refinement of homology-based protein structure models. *Methods Enzymol* 374: 461–491.
- Fritz-Six KL, Dunworth WP, Li M, Caron KM (2008). Adrenomedullin signaling is necessary for murine lymphatic vascular development. *J Clin Invest* 118: 40–50.
- Fujisawa Y, Nagai Y, Miyatake A, Takei Y, Miura K, Shoukouji T *et al.* (2004). Renal effects of a new member of adrenomedullin family, adrenomedullin2, in rats. *Eur J Pharmacol* 497: 75–80.
- Gingell JJ, Qi T, Bailey RJ, Hay DL (2010). A key role for tryptophan 84 in receptor activity-modifying protein 1 in the amylin 1 receptor. *Peptides* 31: 1400–1404.
- ter Haar E, Koth CM, Abdul-Manan N, Swenson L, Coll JT, Lippke JA *et al.* (2010). Crystal structure of the ectodomain complex of the CGRP receptor, a class-B GPCR, reveals the site of drug antagonism. *Structure* 18: 1083–1093.
- Hay DL, Christopoulos G, Christopoulos A, Sexton PM (2006a). Determinants of 1-piperidinecarboxamide, N-[2-[[5-amino-1-[(4-(4-pyridinyl)-1-piperazinyl]carbonyl]pentyl]amino]-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)] (BIBN4096BS) affinity for calcitonin gene-related peptide and amylin receptors – the role of receptor activity modifying protein 1. *Mol Pharmacol* 70: 1984–1991.
- Hay DL, Poyner DR, Sexton PM (2006b). GPCR modulation by RAMPs. *Pharmacol Ther* 109: 173–197.
- Hinson JP, Kapas S, Smith DM (2000). Adrenomedullin, a multifunctional regulatory peptide. *Endocr Rev* 21: 138–167.
- Hoare SR (2005). Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. *Drug Discov Today* 10: 417–427.
- Hollenstein K, Kean J, Bortolato A, Cheng RK, Dore AS, Jazayeri A *et al.* (2013). Structure of class B GPCR corticotropin-releasing factor receptor 1. *Nature* 499: 438–443.
- Hong Y, Hay DL, Quirion R, Poyner DR (2012). The pharmacology of adrenomedullin 2/intermedin. *Brit J Pharmacol* 166: 110–120.
- Ichikawa-Shindo Y, Sakurai T, Kamiyoshi A, Kawate H, Iinuma N, Yoshizawa T *et al.* (2008). The GPCR modulator protein RAMP2 is essential for angiogenesis and vascular integrity. *J Clin Invest* 118: 29–39.
- Kusano S, Kukimoto-Niino M, Hino N, Ohsawa N, Okuda K, Sakamoto K *et al.* (2012). Structural basis for extracellular interactions between calcitonin receptor-like receptor and receptor activity-modifying protein 2 for adrenomedullin-specific binding. *Protein Sci* 21: 199–210.
- Laskowski RA (2001). PDBsum: summaries and analyses of PDB structures. *Nucleic Acids Res* 29: 221–222.
- Laskowski RA, Macarthur MW, Moss DS, Thornton JM (1993). (PROCHECK): a program to check the stereochemical quality of protein structures. *J Appl Cryst* 26: 283–291.
- Li H, Robertson AD, Jensen JH (2005). Very fast empirical prediction and interpretation of protein pKa values. *Proteins* 61: 704–721.
- McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N *et al.* (1998). RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. *Nature* 393: 333–339.
- Miller PS, Barwell J, Poyner DR, Wigglesworth MJ, Garland SL, Donnelly D (2010). Non-peptidic antagonists of the CGRP receptor, BIBN4096BS and MK-0974, interact with the calcitonin receptor-like receptor via methionine-42 and RAMP1 via tryptophan-74. *Biochem Biophys Res Commun* 391: 437–442.
- Moad HE, Pioszak AA (2013). Selective CGRP and adrenomedullin peptide binding by tethered RAMP-calcitonin receptor-like receptor extracellular domain fusion proteins. *Protein Sci* 22: 1775–1785.

- Moore EL, Gingell JJ, Kane SA, Hay DL, Salvatore CA (2010). Mapping the CGRP receptor ligand binding domain: tryptophan-84 of RAMP1 is critical for agonist and antagonist binding. *Biochem Biophys Res Commun* 394: 141–145.
- Pal K, Swaminathan K, Xu HE, Pioszak AA (2010). Structural basis for hormone recognition by the Human CRFR2(alpha) G protein-coupled receptor. *J Biol Chem* 285: 40351–40361.
- Parthier C, Kleinschmidt M, Neumann P, Rudolph R, Manhart S, Schlenzig D *et al.* (2007). Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor. *Proc Natl Acad Sci U S A* 104: 13942–13947.
- Parthier C, Reedtz-Runge S, Rudolph R, Stubbs MT (2009). Passing the baton in class B GPCRs: peptide hormone activation via helix induction? *Trends Biochem Sci* 34: 303–310.
- Pioszak AA, Xu HE (2008). Molecular recognition of parathyroid hormone by its G protein-coupled receptor. *Proc Natl Acad Sci U S A* 105: 5034–5039.
- Pioszak AA, Parker NR, Suino-Powell K, Xu HE (2008). Molecular recognition of corticotropin-releasing factor by its G-protein-coupled receptor CRFR1. *J Biol Chem* 283: 32900–32912.
- Pioszak AA, Parker NR, Gardella TJ, Xu HE (2009). Structural basis for parathyroid hormone-related protein binding to the parathyroid hormone receptor and design of conformation-selective peptides. *J Biol Chem* 284: 28382–28391.
- Poirot O, O'Toole E, Notredame C (2003). Tcoffee@igs: a web server for computing, evaluating and combining multiple sequence alignments. *Nucleic Acids Res* 31: 3503–3506.
- Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W *et al.* (2002). International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. *Pharmacol Rev* 54: 233–246.
- Qi T, Hay DL (2010). Structure-function relationships of the N-terminus of receptor activity-modifying proteins. *Br J Pharmacol* 159: 1059–1068.
- Qi T, Christopoulos G, Bailey RJ, Christopoulos A, Sexton PM, Hay DL (2008). Identification of N-terminal receptor activity-modifying protein residues important for calcitonin gene-related peptide, adrenomedullin, and amylin receptor function. *Mol Pharmacol* 74: 1059–1071.
- Qi T, Ly K, Poyner DR, Christopoulos G, Sexton PM, Hay DL (2011). Structure–function analysis of amino acid 74 of human RAMP1 and RAMP3 and its role in peptide interactions with adrenomedullin and calcitonin gene-related peptide receptors. *Peptides* 32: 1060–1067.
- Qi T, Dong M, Watkins HA, Wootten D, Miller LJ, Hay DL (2013). Receptor activity-modifying protein-dependent impairment of calcitonin receptor splice variant $\Delta(1-47)$ hCT((a)) function. *Br J Pharmacol* 168: 644–657.
- Roh J, Chang CL, Bhalla A, Klein C, Hsu SY (2004). Intermedin is a calcitonin/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor/receptor activity-modifying protein receptor complexes. *J Biol Chem* 279: 7264–7274.
- Runge S, Thogersen H, Madsen K, Lau J, Rudolph R (2008). Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain. *J Biol Chem* 283: 11340–11347.
- Sali A, Blundell TL (1993). Comparative protein modelling by satisfaction of spatial restraints. *J Mol Biol* 234: 779–815.
- Siu FY, He M, de Graaf C, Han GW, Yang D, Zhang Z *et al.* (2013). Structure of the human glucagon class B G-protein-coupled receptor. *Nature* 499: 444–449.
- Takei Y, Hyodo S, Katafuchi T, Minamino N (2004a). Novel fish-derived adrenomedullin in mammals: structure and possible function. *Peptides* 25: 1643–1656.
- Takei Y, Inoue K, Ogoshi M, Kawahara T, Bannai H, Miyano S (2004b). Identification of novel adrenomedullin in mammals: a potent cardiovascular and renal regulator. *FEBS Lett* 556: 53–58.
- Underwood CR, Garibay P, Knudsen LB, Hastrup S, Peters GH, Rudolph R *et al.* (2010). Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor. *J Biol Chem* 285: 723–730.
- Watkins HA, Rathbone DL, Barwell J, Hay DL, Poyner DR (2012). Structure–activity relationships for alpha calcitonin gene-related peptide. *Br J Pharmacol* 170: 1308–1322.
- Watkins HA, Au M, Bobby R, Archbold JK, Abdul-Manan N, Moore JM *et al.* (2013). Identification of key residues involved in adrenomedullin binding to the AM1 receptor. *Br J Pharmacol* 169: 143–155.

Supporting information

Additional Supporting Information may be found in the online version of this article at the publisher's web-site:

<http://dx.doi.org/10.1111/bph.12508>

Figure S1 Effect of mutations in N-terminal CLR residues on $E_{\max}$ values. Data are ordered to show the effect by RAMP (left) or peptide (right). For comparisons with the CGRP receptor, these values were calculated from the data presented in Barwell *et al.* (2010). * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$ versus relevant WT receptor by paired *t*-test.

Figure S2 Amino acid sequence alignment of CLR sequences from selected species: human (*homo sapiens*), chicken (*Gallus gallus*), mouse (*Mus musculus*), rat (*Rattus norvegicus*), pufferfish CLR1 (*Takifugu obscurus*), salmon (*Salmo salar*) and pig (*Sus scrofa*) showing only the ECD helix region. The alignment was generated using Clustal Omega, and ESPript total conservation of residues is shown in red, partial conservation in yellow. The sequence was aligned using the % equivalence algorithm on the basis of physicochemical parameters.